PMID: 7545824Jul 22, 1995Paper

Drug therapy in bronchial carcinoma

Schweizerische medizinische Wochenschrift
C Manegold, P Drings

Abstract

In the treatment of bronchogenic carcinoma approaches vary depending upon whether the carcinoma in question is defined as a small cell or a non-small cell lung cancer. Small-cell lung cancer in the majority of cases must be seen as a systemic disease even with an early diagnosis. Because of this, chemotherapy is the dominant form of treatment. For patients with limited disease radiotherapy and surgery are additionally recommended as potentially curative measures, and for those with extensive disease, surgery and radiotherapy may serve as palliative treatment. Chemotherapy generally consists of a combination of two or more cytostatic drugs. As a rule 4 to 6 treatment cycles are administered. Maintenance therapy appears to be of little value. In case of tumor relapse, new cytostatic combinations can be attempted or the cytostatic regimen which was originally successful can be reintroduced. Whether or not a tumor responds to a particular chemotherapy is apparent after the first cycle of treatment. When the tumor shows no reduction in small-cell lung cancer, the treatment regimen can immediately be changed. The question of possible intensification of induction chemotherapy has yet to be clarified by clinical trials. The data gather...Continue Reading

Related Concepts

Related Feeds

Carcinoma, Bronchogenic

Bronchogenic Carcinoma is a malignant lung cancer arising in the epithelium of the bronchus or bronchiole. Discover the latest research on Bronchogenic Carcinoma here.

Related Papers

Lung Cancer : Journal of the International Association for the Study of Lung Cancer
W Schuette
© 2021 Meta ULC. All rights reserved